Try
Adaptive Biotechnologies Corp
ADPTUnited States
38 filed reports · 350 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
38 reports · Jun 2019 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 18 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 22 | 3,376 | Jun 2019 to Jun 2026 |
| Current · 8-KSEC EDGAR | 9 | 18 | Mar 2021 to Dec 2024 |
| Annual · 10-KSEC EDGAR | 7 | 2,925 | Dec 2019 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 318 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 214 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 776 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 212 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 143 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 163 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 3, 2025 | 406 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 11, 2025 | 2 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 158 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 154 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 154 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 29, 2024 | 340 | Open |
Financial data
350 concepts · 6,319 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial331 concepts · 5,929 facts · Dec 2017 to Jul 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations43 · Dec 2017 to Jun 2026
- Stockholders equity (US GAAP)43 · Dec 2017 to Jun 2026
- Allocated share based compensation expense42 · Dec 2017 to Jun 2026
- Amortization of intangible assets42 · Dec 2017 to Jun 2026
- Comprehensive income net of tax42 · Dec 2017 to Jun 2026
- Cost of goods and services sold (US GAAP)42 · Dec 2017 to Jun 2026
- Costs and expenses42 · Dec 2017 to Jun 2026
- General and administrative expense (US GAAP)42 · Dec 2017 to Jun 2026
- Interest and other income42 · Dec 2017 to Jun 2026
- Net income loss42 · Dec 2017 to Jun 2026
- Operating income loss42 · Dec 2017 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent42 · Dec 2017 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax42 · Dec 2017 to Jun 2026
- Research and development expense42 · Dec 2017 to Jun 2026
- Revenue42 · Dec 2017 to Jun 2026
- Selling and marketing expense (US GAAP)42 · Dec 2017 to Jun 2026
- Stock issued during period value stock options exercised42 · Dec 2017 to Jun 2026
- Accretion amortization of discounts and premiums investments41 · Dec 2017 to Jun 2026
- Capital expenditures incurred but not yet paid41 · Dec 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect41 · Dec 2017 to Jun 2026
- Depreciation41 · Dec 2017 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities41 · Dec 2017 to Jun 2026
- Increase decrease in accounts receivable41 · Dec 2017 to Jun 2026
- Increase decrease in contract with customer liability41 · Dec 2017 to Jun 2026
Segment14 concepts · 268 facts · Dec 2022 to Jun 2026
- Allocated share based compensation expense39 · Dec 2022 to Jun 2026
- Operating Segments36 · Dec 2022 to Jun 2026
- Revenue36 · Dec 2022 to Jun 2026
- Depreciation and amortization28 · Dec 2022 to Jun 2026
- Research and development expense28 · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)14 · Dec 2022 to Jun 2026
- Selling and marketing expense (US GAAP)14 · Dec 2022 to Jun 2026
- Costs and expenses12 · Mar 2023 to Sep 2024
- Net income loss12 · Mar 2023 to Sep 2024
- Profit loss12 · Mar 2023 to Sep 2024
- Restructuring charges11 · Mar 2024 to Jun 2026
- Impairment of long lived assets held for use8 · Jun 2024 to Dec 2024
- Goodwill4 · Dec 2024 to Dec 2025
Product3 concepts · 104 facts · Dec 2017 to Jun 2026
- Revenue73 · Dec 2017 to Dec 2025
- Sequencing Revenue19 · Sep 2019 to Jun 2026
- Contract with customer liability revenue recognized12 · Sep 2019 to Dec 2021
Guidance2 concepts · 18 facts · May 2021 to Feb 2025
- Revenue Guidance16 · May 2021 to Aug 2023
- Free Cash Flow Guidance2 · Feb 2025
Segments
372 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments5 members · 268 facts
- Mrd Business148 · Dec 2022 to Jun 2026
- Immune Medicine Business105 · Dec 2022 to Jun 2026
- Mrd Business Segment And Immune Medicine Business11 · Dec 2023 to Mar 2026
- Immune medicine business2 · Dec 2024 to Dec 2025
- Mrd business segment2 · Dec 2024 to Dec 2025
Product or service7 members · 104 facts
- Sequencing Revenue51 · Dec 2017 to Jun 2026
- Development Revenue20 · Dec 2017 to Dec 2021
- Immune Medicine Service Revenue16 · Dec 2022 to Dec 2025
- Development Support Revenue5 · Dec 2017 to Dec 2021
- Development Revenue Regulatory Milestones4 · Dec 2018 to Dec 2021
- Sequencing Revenue From Coverage Policy4 · Jun 2019 to Dec 2019
- Sequencing Revenue From Test Deliver4 · Jun 2019 to Dec 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.